BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Fisher
H A
HA
Department of Urologic Oncology, Albany Medical College, New York.
D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000628:therapy; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008937:Mitomycins / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D013852:Thiotepa / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000628:therapy*
D001500:BCG Vaccine; D008937:Mitomycins; D004317:Doxorubicin; D013852:Thiotepa